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To the Editor: We recently reported that postvaccina-
tion serum samples from infants immunized with a novel, 
protein-based multicomponent meningococcal serogroup B 
(MenB) vaccine (Bexsero; GlaxoSmithKline Vaccines, Ve-
rona, Italy) have bactericidal activity against the hyperviru-
lent meningococcal group W (MenW) strain belonging to 
the sequence type (ST) 11 clonal complex (1). Historically, 
MenW has been a rare cause of invasive meningococcal 
disease (IMD), accounting for <5% of confirmed cases in 
England and Wales (2). Since 2009, MenW cases caused by 
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this hypervirulent strain have rapidly increased in England 
(2). During the 2014–15 epidemiologic year (July 1–June 
30), this capsular group accounted for 176 (24%) of 724 
IMD cases in England (3). In response to this outbreak, in 
August 2015, the United Kingdom introduced an emer-
gency adolescent conjugate vaccination program against 
meningococcal capsular groups ACW and Y. Over 2 years, 
the program aims to provide vaccine to all youth 13–18 
years of age and to new university entrants <25 years of 
age. This program is expected to protect adolescents (25 
of 176 [14%] MenW cases during 2014–15 were in those 
15–19 years of age), and, by targeting youth with the high-
est carriage rates, to protect others through indirect (herd) 
protection, which has been consistently observed in vac-
cine programs, including that for meningococcal group 
C (4,5). Indirect protection associated with the adoles-
cent immunization program will likely take several years 
to manifest (6).
Infants <1 year of age have the highest incidence of 
IMD and the highest number of IMD cases and deaths (5). 
During the 2014–15, 127 (18%) of the 724 IMD cases in 
England occurred in this group: 101 (80%) meningococ-
cal group B (MenB) cases, 21 (16%) MenW cases, 1 (1%) 
group C case, and 4 (3%) group Y cases (7). In September 
2015, MenB vaccine was introduced into the UK infant 
immunization program under a 2-, 4-, and 12-month sched-
ule. We analyzed the epidemiology and long-term trends for 
MenW disease in infants in England to assess the potential 
effects of the infant MenB immunization program for pre-
venting MenW cases in this highly vulnerable age group.
During the epidemiologic period 1998–99 through 
2014–15, a total of 176 MenW cases were confirmed in 
infants. The number of cases peaked during 2000–01 (n 
= 28) because of a national outbreak associated with the 
Hajj pilgrimage and then declined rapidly after mandatory 
vaccination for pilgrims was instigated (Figure, panel A). 
During that outbreak, most infants acquired the infection 
indirectly from family members who traveled to the Hajj, 
highlighting this group’s susceptibility to IMD. The num-
ber of MenW cases in infants began increasing again from 
4 cases in 2012–13 to 12 in 2013–14 and 21 in 2014–15. 
During 2014–15, these 21 MenW cases represented 16.5% 
of 127 total IMD cases among infants, 12% of 176 total 
MenW cases, and 3% of 724 total IMD cases in England. 
All infants with MenW IMD resided in England and had 
not traveled abroad. The number of MenW cases increased 
from birth among infants, peaking at 4 months of age and 
remaining high until the first birthday. Most (123 [70%]) of 
the 176 MenW cases confirmed during (44/66 [67%]) and 
after (79/110 [72%]) the Hajj outbreak were in persons >5 
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Figure. Incidence of invasive 
meningococcal disease (IMD) in 
infants <1 year of age in England 
during the epidemiologic years 
1998–99 through 2014–15. A) 
Incidence of IMD and phenotypic 
characterization of laboratory-
confirmed meningococcal group 
W strains in infants <1 year 
of age. B) Total laboratory-
confirmed meningococcal group 
W cases in infants <1 year of 
age by month of age. Cases 
related to the Hajj outbreak 
occurred during 1999–00 
through 2001–02.
months of age and were potentially preventable by MenB 
vaccine vaccination.
During 2012–13 through 2014–15, a total of 25 (67.5%) 
of 37 MenW cases in infants were confirmed by culture; 18 
(49%) of these cases were phenotypically characterized as 
MenW:2a, a surrogate phenotypic marker for the hyperviru-
lent ST11 MenW strain. Ten (48%) of the 21 isolates from 
infants during 2014–15 were MenW:2a, compared with 1 
(25%) of 4 during 2012–13 (Figure, panel B). Final diag-
noses reported for 20 infants included meningitis (n = 10 
[50%]), septicemia (n = 3 [15%]), both meningitis and septi-
cemia (n = 5 [10%]), and septic arthritis (n = 1 [2%]). From 
1998–99 through 2014–15, six infants died of MenW IMD 
(case-fatality rate 3.4%). Four of those deaths occurred dur-
ing the Hajj outbreak; only 1 death attributed to MenW oc-
curred during the 3 most recent epidemiologic years.
The rapid increase in MenW cases among infants, 
particularly most recently (2014–15), is cause for concern, 
and the contemporaneous introduction of MenB vaccine 
into the national immunization schedule is timely. Al-
though this vaccine is licensed for prevention of MenB 
disease, the antigens are not specific to this capsular group 
and could protect against other meningococcal capsular 
groups that share the same antigens as those in the vac-
cine. Infants and toddlers immunized with MenB vaccine 
are expected to develop bactericidal antibodies against 
ST11 MenW. Data on age distribution suggest that ≈70% 
of MenW cases in infants could be prevented by MenB 
vaccination at 2 and 4 months of age. Beginning in mid-
2016, the MenB vaccine booster for children 1 year of age 
is also expected to protect toddlers, for whom MenW cases 
have also rapidly increased (3).
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